RxDoctor Payments Data

Gary Tanner, MD

Ophthalmology · Newport News, VANPI 1851364772

Payments from drug & device makers

$1,347in general payments, 2019–2025

Across 26 payments — averaging $51.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$425
  • Alcon$348
  • Aerie Pharmaceuticals, Inc.$266
  • Apellis Pharmaceuticals, Inc.$93
  • Harrow Eye, LLC$58
  • Oyster Point Pharma, Inc.$34
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$1,347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,347 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$438,037
Medicare patients
1,447
Services billed
3,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine88$130,373
LumiganBimatoprost75$49,611
RhopressaNetarsudil Mesylate31$19,746
Cyclosporine32$16,707
Travoprost67$9,822
SimbrinzaBrinzolamide/Brimonidine Tart16$8,837
Brimonidine Tartrate103$8,502
RocklatanNetarsudil Mesylat/Latanoprost12$7,335
Timolol Maleate146$6,320
CombiganBrimonidine Tartrate/Timolol16$5,892
Latanoprost666$5,147
Fluorometholone23$1,370
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$999
Prednisolone Acetate21$826
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$425$185,876179 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$266$27,08143 claims
AlconSimbrinza$348$8,83716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →